Axonis Therapeutics

Axonis Therapeutics is a biotechnology company developing first- and best-in-class medicines targeting KCC2, a critical mediator of inhibitory neurotransmission in the brain. Their lead candidate, AXN-027, is an oral small molecule designed to treat epilepsy and pain by potentiating KCC2 function. The company aims to restore functional inhibition in the CNS to treat neurological disorders without disabling side effects.

Buy Download

Funding Round: Series A

Funding Amount: $115M

Date: 30-Oct-2024

Investors: Cormorant Asset Management, venBio Partners, Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, Lumira Ventures, Solasta Ventures, Eos Bioinnovation, Hatteras Venture Partners, SCI Ventures, Alexandria Venture Investments, Tachyon Ventures, BoxOne, Iaso Ventures, Pathway Bioventures

Markets: Biotechnology, Neuroscience, Neurology, Pharmaceutical, Drug Discovery

HQ: Boston, Massachusetts, United States

Founded: 2019

Website: https://www.axonis.us/

LinkedIn: https://www.linkedin.com/company/axonis-us

Twitter: https://twitter.com/axonis_us

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/axonius-ca2a?utm_source=linkedin&utm_medium=referral&utm_campaign=linkedin_companies&utm_content=profile_cta_anon&trk=funding_crunchbase

Pitchbook: https://pitchbook.com/profiles/company/434842-66

Buy Download